Trial Profile
Nivolumab in Non Small Cell Lung Cancer Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Jun 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.